On the morning of June 13, Professor Qu Wenchun, Director of Regenerative Pain Medicine at Mayo Clinic and head of its Cell & Gene Therapy Center along with the GMP Biomanufacturing Center, led a delegation to visit Shenzhen-Hong Kong Cell Valley. The delegation was warmly received by Professor Shi Yuanyuan, founder of Shenzhen-Hong Kong Cell Valley; Chief Medical Expert Professor David Jin; and Chief Scientist Professor Wang Jianxun. They engaged in academic exchanges and jointly explored strategic cooperation directions.

This visit coincides with a pivotal moment in China's cell therapy industry development. With policy incentives taking effect, Shenzhen-Hong Kong Cell Valley – the first foreign-invested demonstration project for cell and gene therapy technology applications in Shenzhen Shekou Free Trade Zone – is accelerating the global expansion of domestic cell products. Professor Qu Wenchun conducted a focused inspection of the international headquarters of Cell Valley Group, Shenzhen-Hong Kong Cell Valley. Professor Qu expressed high praise for Cell Valley's achievements in CAR-T, CAR-NK, and exosome-based cell therapies, including their R&D, production processes, and quality control systems. Both parties reached preliminary strategic cooperation intentions regarding CAR-T target screening, viral vector mass production, and clinical translation research. Professor Shi Yuanyuan stated: "Leveraging the policy advantages of Qianhai Free Trade Zone, we look forward to collaborating with Mayo Clinic to establish an international benchmark for cell therapy clinical translation, enabling innovative outcomes to benefit patients worldwide." This exchange will enhance Cell Valley's global influence in the cell therapy field.